These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32141676)

  • 1. Risk factors for second-line dactinomycin failure after methotrexate treatment for low-risk gestational trophoblastic neoplasia: a retrospective study.
    Hoeijmakers YM; Sweep F; Lok C; Ottevanger PB
    BJOG; 2020 Aug; 127(9):1139-1145. PubMed ID: 32141676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum hCG level and rising world health organization score at second-line chemotherapy (pulse dactinomycin): poor prognostic factors for methotrexate-failed low-risk gestational trophoblastic neoplasia.
    Kang WD; Kim CH; Cho MK; Kim JW; Cho HY; Kim YH; Choi HS; Kim SM
    Int J Gynecol Cancer; 2010 Nov; 20(8):1424-8. PubMed ID: 21051988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Second-Line 5-Day Dactinomycin in Case of Methotrexate Failure for Gestational Trophoblastic Neoplasia.
    Prouvot C; Golfier F; Massardier J; You B; Lotz JP; Patrier S; Devouassoux M; Schott AM; Hajri T; Bolze PA
    Int J Gynecol Cancer; 2018 Jun; 28(5):1038-1044. PubMed ID: 29629964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia.
    Winter MC; Tidy JA; Hills A; Ireson J; Gillett S; Singh K; Hancock BW; Coleman RE
    Gynecol Oncol; 2016 Dec; 143(3):565-570. PubMed ID: 27756557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Combination Therapy with Actinomycin D and Methotrexate in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia.
    Kang HL; Zhao Q; Yang SL; Duan W
    Chemotherapy; 2019; 64(1):42-47. PubMed ID: 31163446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the Predictive Value of Modeled Human Chorionic Gonadotrophin Residual Production in Low-Risk Gestational Trophoblastic Neoplasia Patients Treated in NRG Oncology/Gynecologic Oncology Group-174 Phase III Trial.
    You B; Deng W; Hénin E; Oza A; Osborne R
    Int J Gynecol Cancer; 2016 Jan; 26(1):208-15. PubMed ID: 26569059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 30-year experience in using oral methotrexate as initial treatment for gestational trophoblastic neoplasia regardless of risk group.
    Faaborg L; Niemann I; Ostenfeld EB; Hansen ES; Sunde L; Lindegaard JC
    Acta Oncol; 2016; 55(2):234-9. PubMed ID: 26106854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia.
    Lybol C; Sweep FC; Harvey R; Mitchell H; Short D; Thomas CM; Ottevanger PB; Savage PM; Massuger LF; Seckl MJ
    Gynecol Oncol; 2012 Jun; 125(3):576-9. PubMed ID: 22410329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human chorionic gonadotropin (hCG) regression normograms for patients with high-risk gestational trophoblastic neoplasia treated with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy.
    Lybol C; Westerdijk K; Sweep FCGJ; Ottevanger PB; Massuger LFAG; Thomas CMG
    Ann Oncol; 2012 Nov; 23(11):2903-2906. PubMed ID: 22730100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors of relapse in low-risk gestational trophoblastic neoplasia patients successfully treated with methotrexate alone.
    Couder F; Massardier J; You B; Abbas F; Hajri T; Lotz JP; Schott AM; Golfier F
    Am J Obstet Gynecol; 2016 Jul; 215(1):80.e1-7. PubMed ID: 26829503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Chorionic Gonadotropin (hCG) Regression Curve for Predicting Response to EMA/CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide and Vincristine) Regimen in Gestational Trophoblastic Neoplasia.
    Rattanaburi A; Boonyapipat S; Supasinth Y
    Asian Pac J Cancer Prev; 2015; 16(12):5037-41. PubMed ID: 26163637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy.
    Chapman-Davis E; Hoekstra AV; Rademaker AW; Schink JC; Lurain JR
    Gynecol Oncol; 2012 Jun; 125(3):572-5. PubMed ID: 22449733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of primary chemotherapy with single methotrexate on low-risk gestational trophoblastic neoplasia and influencing factors thereof].
    Chen YX; Shen YM; Qian JH; Xie X
    Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2109-12. PubMed ID: 16313819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Oral Vitamin A in Reducing β-hCG Levels in Low-Risk Gestational Trophoblastic Neoplasia Patients.
    Hidayat YM; Darmadi A E; Rachmayati S; Kusumah WP; Djuwantono T; Pramatirta AY; Suardi D
    Asian Pac J Cancer Prev; 2020 Nov; 21(11):3325-3329. PubMed ID: 33247691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy analysis of single-agent carboplatin AUC4 2-weekly as second-line therapy for methotrexate-resistant (MTX-R) low risk gestational trophoblastic neoplasia (GTN).
    Winter MC; Tidy JA; Singh K; Sarwar N; Aguiar X; Seckl MJ
    Gynecol Oncol; 2023 Aug; 175():66-71. PubMed ID: 37327541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early prediction of post-molar gestational trophoblastic neoplasia and resistance to methotrexate, based on a single serum human chorionic gonadotropin measurement.
    Hoeijmakers YM; Eysbouts YK; Massuger LFAG; Dandis R; Inthout J; van Trommel NE; Ottevanger PB; Thomas CMG; Sweep FCGJ
    Gynecol Oncol; 2021 Dec; 163(3):531-537. PubMed ID: 34602288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?
    Miller CR; Chappell NP; Sledge C; Leath CA; Phippen NT; Havrilesky LJ; Barnett JC
    Gynecol Oncol; 2017 Jan; 144(1):125-129. PubMed ID: 27816248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of an online tool for early prediction of the failure-risk in gestational trophoblastic neoplasia patients treated with methotrexate.
    Dekeister K; Bolze PA; Tod M; Tod R; Massardier J; Lotz JP; Hajri T; Colomban O; Seckl MJ; Osborne R; Freyer G; Golfier F; You B
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):15-24. PubMed ID: 32500221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulse methotrexate versus pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia.
    Yarandi F; Eftekhar Z; Shojaei H; Kanani S; Sharifi A; Hanjani P
    Int J Gynaecol Obstet; 2008 Oct; 103(1):33-7. PubMed ID: 18632105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors related to treatment outcomes in low-risk gestational neoplasia.
    Turkmen O; Basaran D; Karalok A; Kimyon GC; Tasci T; Ureyen I; Tulunay G; Turan T
    Tumori; 2017 Mar; 103(2):177-181. PubMed ID: 27514315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.